Current Report Filing (8-k)
May 23 2019 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 17, 2019
RUBICON TECHNOLOGY, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-33834
|
|
36-4419301
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
900 East Green Street
Bensenville, Illinois
|
|
60106
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(847) 295-7000
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On May 23, 2019, the Company
issued a press release announcing the Launch of Direct Dose Rx. A copy of the press release is attached hereto as Exhibit 99.1.
The above information
(including Exhibit 99.1) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor
shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as may be
expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The following exhibits are filed or furnished as part of this report:
** Furnished herewith.
1
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
RUBICON TECHNOLOGY, INC.
|
|
|
|
Dated: May 23, 2019
|
By:
|
/s/ Timothy E. Brog
|
|
Name:
|
Timothy E. Brog
|
|
Title:
|
Chief Executive Officer, President and Interim Chief Financial Officer
|
2
EXHIBIT INDEX
** Furnished herewith.
Rubicon Technology (NASDAQ:RBCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubicon Technology (NASDAQ:RBCN)
Historical Stock Chart
From Sep 2023 to Sep 2024